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Colorectal cancer (CRC) poses a substantial public 
health problem, with global incidence set to eclipse  two  
 
million by 2030 [1]. In Europe, CRC represents the 
second highest cause of cancer-related death, healthcare 
expenditure, and loss of productivity [2]. The principal 
cause of mortality from CRC is metastasis. Despite 
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Colorectal  cancer  is  a  global  disease with  increasing  incidence. Mortality  is  largely  attributed  to metastatic
spread  and  therefore,  a mechanistic  dissection  of  the  signals which  influence  tumor  progression  is needed.
Cancer  stroma plays a critical  role  in  tumor proliferation,  invasion and chemoresistance. Here, we  sought  to
identify  and  characterize  exosomal  microRNAs  as  mediators  of  stromal‐tumor  signaling.  In  vitro,  we
demonstrated that  fibroblast exosomes are transferred to colorectal cancer cells, with a resultant  increase  in
cellular  microRNA  levels,  impacting  proliferation  and  chemoresistance.  To  probe  this  further,  exosomal
microRNAs  were  profiled  from  paired  patient‐derived  normal  and  cancer‐associated  fibroblasts,  from  an





confirmed  the  importance of  stromal miR‐21  in  colorectal  cancer progression using  an orthotopic model,  and
propose that exosomes are a vehicle for miR‐21 transfer between stromal fibroblasts and cancer cells. 
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advances in surgical and chemotherapeutic treatment 
options for metastatic CRC, the majority of patients 
remain incurable, with a median survival of less than 
two years [3]. This highlights the need to identify novel 
therapeutic targets and better markers of metastatic 
capability, enabling stratification of high-risk patients 
for treatment intensification and less radical treatment 
for lower risk disease. 
 
The consensus view of a tumor resembling an organ has 
highlighted the critical role of the tumor microenviron-
ment in recent years [4]. The shift in focus has revealed 
that stromal cells such as cancer-associated fibroblasts 
(CAFs) are key players in modulating tumor progression 
[5-7]. Moreover, a dynamic and reciprocal interaction 
between cancer and stromal cells has been demonstrated, 
highlighting the profound impact that stromal cells have 
on proliferation, angiogenesis, invasion, metastasis and 
chemoresistance, thereby promoting cancer progression 
through multiple pleiotropic mechanisms [5-7]. It is 
therefore understandable, that a significant number of 
genes which stratify better and worse prognoses, are 
defined by the stromal compartment [8]. 
 
MicroRNAs (miRNAs) are small non-coding RNAs that 
negatively regulate gene expression and have been 
shown to control many cellular genes and pathways. 
Recent work by our group has revealed that deregulated 
miRNA expression in CRC stroma is of clinical 
significance [9, 10]. One miRNA taken forward was 
miR-21, an oncogenic miRNA overexpressed in several 
solid tumors, which regulates the tumor suppressor 
PDCD4 in CRC [11, 12]. Whilst previous studies 
identified miR-21 upregulation in CRC, these consider-
ed whole-tissue only [13, 14]. In contrast, we and others 
have shown that miR-21 is overexpressed in CRC stroma 
by CAFs, stratifying patients with early-stage CRC for 
recurrence, disease free survival and overall survival 
[10]. Mechanistically, we demonstrated that over-
expression of miR-21 in CAFs promotes increased 
invasiveness, proliferation and chemotherapy resistance 
in surrounding tumor cells by paracrine signaling [9]. 
Clearly then, it is important to elucidate mechanisms by 
which stromal gene expression is relayed to cancer cells. 
Exosomes provide one such mechanism [15]. 
 
Exosomes are 40-100 nm extracellular vesicles which 
participate in a variety of physiological and pathological 
processes [16]. Their cargo includes proteins, mRNAs 
and miRNAs, which can be shuttled between cells to 
facilitate intercellular communication [17]. An increas-
ing body of evidence shows that exosomes play critical 
roles in several aspects of cancer progression, ranging 
from proliferation, invasion, metastasis, pre-metastatic 
niche formation and metastatic organotropism [18-23]. 
Furthermore, stromal exosomes containing non-coding 
RNAs have been shown to increase chemo- and radio-
resistance by modifying gene expression in recipient 
cancer cells [15].  
 
With a focus on CAFs as stromal drivers of tumor 
progression, we aimed to investigate the exosome-
mediated crosstalk between CAFs and cancer cells. To 
achieve this, we derived paired normal and cancer-
associated colorectal fibroblasts from human donors, 
isolated exosomes, and profiled their miRNA content 
using a high sensitivity direct detection array (Nano-
String). Here, for the first time, we identify a novel 
stromal exosome signature in CRC, as part of a 
prospective biomarker study. Furthermore, we reiterate 
the importance of stromal miR-21 in CRC progression 
using an orthotopic murine model and demonstrate that 
one of the mechanisms of miR-21 transfer between stro-




Characterization of fibroblast exosomes 
 
In order to isolate exosomes from MRC5 fibroblasts, 
differential ultracentrifugation was performed, 
producing an exosome pellet which was enriched in 
vesicle-associated tetraspanins (CD63 and CD81), 
endosomal proteins (TSG101 and Alix), and devoid of 
organelle-specific markers such as GM130 (Golgi) and 
cytochrome C (mitochondria; Fig. 1A). Unfixed MRC5 
exosomes visualized by transmission electron micro-
scopy (TEM) demonstrated a uniformly circular 
morphology with size distribution 40-120 nm (80 000x) 
and at higher magnification (120 000x) the lipid bilayer 
structure was clearly seen (Fig. 1B), in keeping with 
previous descriptions [16]. Nanoparticle tracking 
analysis (NTA) confirmed a modal size of 113+/-1.3 nm 
and exosome concentration of 1.57+/-0.16 x1012/ ml, 
which corresponded with a protein concentration of 
0.50+/-0.04 μg/μl (Fig. 1C; data not shown). Bioanalyzer 
analysis of exosomal RNA showed presence of small 
RNAs and paucity of 18s and 25s ribosomal RNA 
subunits when compared to cellular RNA (Supplemen-
tary Fig. 1), in keeping with previous findings [24].  
 
This meets criteria set by the International Society for 
Extracellular Vesicles for characterizing extracellular 
vesicles [25]. Furthermore, our exosome isolation and 
characterization protocol was assigned an Extracellular 
Vesicle (EV) Metric of 77% which is in the 99th 
percentile for all experiments on the same sample type 
[26]. Finally, the exosome preparations described here 
could potentially contain other extracellular vesicle 
populations but given the enrichment of endosomal 
markers and size distribution, the predominant vesicle 
type is likely to be exosomes. 

















































































































assess expression of exosomal markers  in MRC5 exosomes. “Cells”  refers  to  total cellular protein, “all EVs”  refers  to  the
total vesicular fraction isolated by a single ultracentrifugation of conditioned medium at 100 000 g, and “exosomes” refers






Figure 2. Fibroblast exosomes are taken up by CRC cells resulting  in  increased miRNA  levels.  (A) Culture of mCherry‐
tagged  DLD1  cells  (red)  in  the  absence  (top)  or  presence  (bottom)  of  DiO‐labelled  MRC5  exosomes  (green),  visualized  by
fluorescence microscopy (10x). Co‐localization of exosomes with cells is demonstrated by arrows. (B) Culture of mCherry‐DLD1 cells
with DiO‐labelled MRC5 exosomes visualized by confocal microscopy (60x), demonstrating the presence of exosomes within cells.
(C)  Flow  cytometry of DLD1  cells  (control) and DLD1  cells  co‐cultured with MRC5 exosomes  (exosome). The proportion of  cells
under the M1 region is given as a percentage. (D) Co‐culture of MRC5 exosomes with DLD1 and SW480 cells with resultant increase
in miR‐29b‐3p, miR‐21‐5p and miR‐16‐5p. Data is presented as mean +/‐ SEM. Paired t‐test: * p<0.05, ** p<0.01, *** p<0.001.  
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Transfer of fibroblast exosomes to CRC cells occurs 
and results in increased miRNA levels 
 
We next sought to examine cellular uptake of fibroblast 
exosomes by CRC cells. To achieve this, DiO-labeled 
MRC5 exosomes (green) were co-cultured with DLD-1 
cells stably expressing mCherry (red) for 24 h. 
Fluorescence microscopy showed co-localization of 
exosomes with cells (Fig. 2A) and confocal imaging 
confirmed their intracellular location (Fig. 2B). In 
addition, using flow cytometry, we were able to 
quantify the extent of exosome uptake (Fig. 2C). 
Subsequently, to investigate whether fibroblast 
exosomes can alter miRNA levels in target cells, we co-
cultured MRC5 exosomes with two different CRC cells, 
DLD1 and SW480. This led to a consistent and 
significant increase in several miRNAs (Fig. 2D). 
 
Fibroblast exosomes have effects on chemotherapy 
resistance and proliferation 
 
Having shown that fibroblast exosomes can be 
transferred to CRC cells, we investigated effects on 
cellular signaling pathways and the functional 
consequences of these. MRC5 exosomes increased ERK 































Similarly, AKT phosphorylation increased, resulting in 
phosphorylation of a direct AKT target, Bad, at amino 
acid 99 (Fig. 3A, middle, right) [27]. This was 
associated with a protective effect on CRC cells in the 
presence of Oxaliplatin, a first line agent in neoadjuvant 
and adjuvant treatment of CRC (Fig. 3B, Sup-
plementary Fig. 2) [28]. Contrary to expectation, there 
was a sustained proliferation defect in DLD1 cells (Fig. 
3C).  
 
Having established that exosomes from a normal 
fibroblast line have functional effects on CRC cells, we 
sought to characterize the cargo of tissue-specific 
normal (NOF) and CAF exosomes. To achieve this, we 
established a library of paired patient-derived primary 
colorectal NOFs and CAFs from which exosomes could 
be derived. 
 
CAFs display a myofibroblastic phenotype and CAF 
exosomes are also transferred to CRC cells 
 
In order to demonstrate phenotypic differences between 
NOFs and CAFs, matched pairs of ex vivo colorectal 
NOFs and CAFs were isolated and characterized using a 
panel of established experimentally validated markers 
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than NOFs in two dimensions (Fig. 4B-D), in keeping 
with previous studies [33]. Intensity of phalloidin 
staining for F-actin filaments was also significantly 
higher in CAFs compared to NOFs (Fig. 4C, E), 
indicating a higher stress fiber density [34]. Similarly to 
MRC5 exosomes, CAF exosomes were transferred to 
DLD1 cells (Fig. 4F), resulting in increased miRNA 
levels (Fig. 4G). 
 
CAF and NOF exosomes are distinguishable by a 
specific miRNA signature 
 
To identify differentially abundant miRNAs, exosomes 
were isolated from ex vivo cultures of primary NOF-
CAF pairs and RNA subjected to NanoString assay. 
Hierarchical cluster analysis of NanoString data 
separated NOF and CAF exosomes according to 
miRNA expression, with nine of the 20 most-changing 
miRNAs less abundant in CAF exosomes and 11 more 





































panel of miRNAs beyond these, we established 
stringent criteria such that candidate miRNAs had to be: 
(i) oncogenic, (ii) stromal in origin, (iii) abundant in 
exosomes and (iv) enriched in exosomes. Ten 
experimentally validated oncomirs were selected: miR-
21, miR-135b, miR-20a/20b, miR-19b, miR-19a, miR-
155, miR-181a, miR-130b, miR-95 and miR-499a [35]. 
Normalized NanoString counts are shown for three 
NOF-CAF exosome pairs with respect to these 
oncomirs (Supplementary Fig. 4).  
 
With a focus on miRNAs which were deliverable in 
CAF exosomes, we validated six miRNAs (miR-329-
3p, miR-181a-3p, miR-199b-5p, miR-382-5p, miR-215-
5p and miR-21-5p) which were more rather than less 
abundant in CAF compared to NOF exosomes (Fig. 6). 
There was significant correlation between NanoString 
and RT-qPCR fold changes for NOF-CAF exosomes 
(R2=0.81; p=0.04), confirming validity of the 






































CRC  cells.  (A)  Western  blot  of  paired  primary  NOFs  and  CAFs  for  myofibroblastic  markers  alpha‐smooth  muscle  actin  (α‐SMA),
fibronectin ED‐A (ED‐A FN1), palladin and vimentin. HSC‐70 was used as an equal loading control. (B) Light microscopy of representative


























































































































Figure 6. qPCR validation  confirms  signature of 6 miRNAs more abundant  in CAF  than NOF exosomes.
Taqman qPCR  results presented as  relative  fold  changes between NOF and CAF exosomal miRNA  for each NOF‐CAF
exosome pair. NOF exosome miRNA level was assigned the value 1 for each NOF‐CAF exosome pair (n=3), each of which
were analyzed in triplicate. Data is presented as mean +/‐ SEM. Student’s t‐test: * p<0.05, ** p<0.01, *** p<0.001. 
www.aging‐us.com  2672  AGING 
Exosomal miRNA signature targets multiple cancer-
relevant pathways 
 
More than 99% of the total 236 Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways have miRNA 
sources and targets in man, emphasizing the vast impact 
of miRNA-mediated regulation within biological 
pathways. KEGG pathways regulated by miRNAs have 
tens of thousands miRNA-gene interactions. The number 
of miRNA-gene interactions related to biological 
pathways in KEGG for our putatively annotated miRNAs 
were, respectively, 174: hsa-miR-181a-3p, 299: hsa-miR-
199b-5p, 128: hsa-miR-382-5p and 1438: hsa-miR-21-
5p. Of these, miR-21 may have the highest regulatory 
activity of biological pathways by targeting over 1400 
genes. We identified 36 KEGG pathways targeted by the 
combined miRNA signature, including “miRNAs in 
cancer”, “proteoglycans in cancer”, “colorectal cancer” 
and “pathways in cancer” (Supplementary Table 1, 
Supplementary Fig. 6). This was reiterated by Ingenuity 
Pathway Analysis (Supplementary Tables 2, 3).  
 
A novel approach to identify miRNA-small molecule 
interactions revealed that this miRNA signature 
interacts with several drugs utilized in cancer therapy. 
Of note, we identified a recurrent association between 
miR-21 and 5-fluorouracil (5-FU), a first line agent in 
neoadjuvant, adjuvant and palliative CRC 
(Supplementary Table 4) [28, 36].  
 
MiR-21 is upregulated in colorectal cancer 
fibroblasts, enriched in their exosomes and its 
ectopic overexpression enhances CRC metastasis in 
an orthotopic CRC murine model 
 
We have previously shown that miR-21 is a stromal 



















influence cancer cells by paracrine mechanisms [9, 10]. 
Cellular and exosomal profiles of NOFs and CAFs in 
this study reinforced this, with significantly higher miR-
21 levels in CAFs compared to NOFs (Fig. 7A, B). 
Importantly, we already showed that CAF exosomes 
contain miR-21 (Fig. 5) and that delivery of CAF 
exosomes to CRC cells results in increased miR-21 
(Fig. 4G). In keeping with this, normalized miRNA 
counts show an abundance of miR-21 in primary 
fibroblast exosomes (Supplementary Fig. 4). Further-
more, miR-21 was the only miRNA enriched in 
exosomes compared to parent cells (Fig. 7C). Hence, 
miR-21 meets all the criteria set above, in that it is 
oncogenic, stromal in origin, abundant in exosomes and 
enriched in exosomes, and was therefore the subject of 
our in vivo study.  
 
Firstly, in order to demonstrate that injected human 
fibroblasts persist in murine xenografts, we co-injected 
PKH26-labeled MRC5 cells (red) with CRC cells to 
form subcutaneous tumors in immunodeficient nude 
mice. The PKH26 signal was detectable five weeks 
after injection (Fig. 8A), suggesting that injected 
fibroblasts persist in the microenvironment of these 
tumors. 
 
To date, no direct role for stromal miRNAs in 
promoting metastasis has been shown in an in vivo CRC 
model. In part, this reflects the limitations posed by 
conventional non-metastatic heterotopic xenografts. 
Consequently, we next sought to evaluate the in vivo 
activity of miR-21 using an orthotopic CRC model, 
modified from our previous description [37]. MiR-21 or 
control non-targeting sequence (control) was stably 
overexpressed in MRC5 fibroblasts as previously 
described [9]. Direct cecal co-implantation of SW620 





















Figure  7.  MiR‐21  is  more  abundant  in  CAF  cells  and  exosomes  and  enriched  in  the  exosomal
compartment. (A) On a whole‐cell level, CAFs express significantly more miR‐21 than NOFs. (B) CAF exosomes contain
significantly more miR‐21 than NOF exosomes. Results obtained by Taqman qPCR and presented as mean relative fold
changes  for  each  NOF‐CAF  pair  (n=3),  analyzed  in  triplicate.  (C)  NanoString  counts  normalized  by  global  mean
expression for CAF cells and exosomes. Exosomal counts are expressed relative to cellular counts which were assigned
the value 1. Data is presented as mean +/‐ SEM. Student’s t‐test: ns – not significant, * p<0.05, ** p<0.01, *** p<0.001.
www.aging‐us.com  2673  AGING 
miR-21 (SW620/MRC5-miR-21) resulted in a greater 
number and size of metastatic tumor deposits in the 
liver when compared to control (SW620/MRC5-
control), equating to eight times more liver replacement 
by secondary CRC deposits (Fig. 8B-D). No metastases 
were noted in the spleens of either group. Histological 
analysis confirmed the presence of colorectal 




In the present study, we isolated and characterized 
exosomes from fibroblasts, and demonstrated that these 
are transferable to CRC cells. Importantly, we showed 
that fibroblast exosomes contain miRNAs, and when 
transferred, miRNA levels are altered recipient cells, 
resulting in functional effects on cell cycle and 
apoptosis. For the first time, we have extracted and 





































isolated their exosomes, and profiled the exosomal 
miRNA cargo using NanoString. This has revealed a 
novel CAF exosomal signature consisting of miR-329, 
miR-181a, miR-199b, miR-382, miR-215 and miR-21, 
which have been shown to regulate multiple cancer-
relevant pathways across several tumor types [12, 38-
42].  
 
The identification of a stromal exosome signature in 
CRC has important implications for biomarker 
development. Firstly, miRNA expression profiles 
effectively classify cancer into subtypes, and miRNAs 
have long been proposed as suitable diagnostic and 
prognostic biomarkers in various cancers [43]. Existing 
biomarkers for CRC, such as carcinoembryonic antigen, 
are known to be poorly sensitive, particularly in the 
diagnostic setting [44]. Secondly, the stroma is a key 
determinant of cancer development and progression [4, 







































of  tumor  section  generated  by  subcutaneous  co‐injection  of  PKH26‐labeled  MRC5  fibroblasts  (red)  and  CRC  cells,
counterstained with DAPI  (blue; 60x).  (B) Liver  (L), spleen  (S) and colon  from mice orthotopically  injected with SW620  CRC
cells and MRC5 control or miR‐21‐overexpressing  fibroblasts. Arrowheads highlight  liver metastases.   The effect of miR‐21‐
overexpressing  cells was  to  increase  the  size and number of  liver metastases.   No  splenic metastases were  seen  in either
group.  (C)  Representative  liver  sections  at  2x  and  100x  magnification.   Bulky  hepatic  metastases  are  evident  in  the
SW620/MRC5‐miR‐21 liver (arrowheads; 2x) with a clear histological demarcation  between normal liver and metastatic tumor
(NT  –  normal  tissue,  T  –  tumor;  100x).  (D)  Percentage  liver  replacement  by metastatic  tumor  in   SW620/MRC5‐control
(control) and SW620/MRC5‐miR‐21 (miR‐21) mice. Data is presented as mean +/‐ SEM. Student’s t‐test: *** p<0.001. 
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mal miRNAs as prognostic markers in CRC [10, 45]. In 
addition, the stromal compartment of a tumor is 
genetically more stable than the cancer compartment 
[46]. Therefore, there should be less variability in 
stromal miRNA profiles compared to cancer cell or 
whole tumor profiles, increasing reproducibility across 
patients. Lastly, exosome encapsulated miRNAs have 
proven to be representative of the tumor, protected from 
degradation, and disseminated in the circulation, which 
improves their utility as circulating biomarkers and 
liquid biopsy material [47-51]. 
 
From our profiling data, we were particularly interested 
in identifying miRNAs of stromal origin with relevance 
in CRC. Considering that we were looking for miRNAs 
that could be transmitted to cancer cells from the 
stroma, we focused on those with known oncogenic 
effects [35]. Additionally, the selected miRNAs had to 
be abundantly expressed in CAF exosomes such that 
significant amounts could be delivered to CRC cells. 
We found that miR-21 met all these criteria (Supple-
mentary Fig. 4, Fig. 4G).  
 
MiR-21 is widely accepted to have oncogenic effects 
across several tumor types [12, 52]. Its most well 
described interactions are with the tumor suppressors 
PTEN and PDCD4 [12, 52-57]. In the context of CRC, 
Asangani and colleagues demonstrated an inverse 
correlation between miR-21 and PDCD4 in multiple 
CRC cell lines, with direct binding to its 3’UTR, 
leading to increased invasive capability [12]. We and 
others have previously demonstrated that miR-21 is a 
stromal signal in CRC, using techniques such as in situ 
hybridization and laser capture microdissection [9, 10, 
58]. This seems to be a generalizable finding spanning 
different solid tumors [59, 60]. Interestingly, Yeung et 
al. recently demonstrated the role of stromal exosomes 
in promoting chemoresistance in ovarian cancer [59]. In 
this study, exosomes derived from miR-21-over-
expressing MEFs (miR-21-MEFs) were transferred to 
ovarian cancer cells, showing that miR-21 is delivered 
by exosomes.  Subcutaneous ovarian cancer xenografts 
were then established by co-injection of cancer cells and 
miR-21-MEFs. Intratumoral taxol injection had 
significantly less effect on tumor burden in xenografts 
containing miR-21-MEFs compared to control. We took 
a similar approach in CRC but used orthotopic 
xenografts, which provide a more reproducible 
metastatic model of CRC [61, 62]. Here, we showed 
that stromal miR-21 is responsible for increased CRC 
metastasis in vivo (Fig. 8B-D). In terms of a 
mechanism, we previously demonstrated that the 
secretome of miR-21-overexpressing fibroblasts directly 
increases proliferative and invasive capacity of CRC 
cells [9]. We present evidence here that one component 
of the secretome, exosomes, are abundant and enriched 
in miR-21 (Fig. 7C, Supplementary Fig. 4). Further-
more, transfer of CAF exosomes results in increased 
miR-21 in recipient CRC cells (Fig. 4G). Based on 
these observations, we propose that in the CRC 
microenvironment, CAFs deliver miR-21 to cancer cells 
in exosomes, promoting metastatic cancer progression. 
Of course, this is one mechanism of stromal-tumor 
crosstalk and others may exist in parallel, such as CAF-
derived soluble factors (e.g. TGBβ, SDF1) and 
juxtacrine signaling [63, 64].   
 
In this study, for the first time, we derived paired 
primary NOFs and CAFs from CRC specimens, isolated 
their exosomes and interrogated their miRNA cargo. 
We identified a novel miRNA signature specific to CAF 
exosomes, consisting of miRNAs which have proven 
relevance in cancer biology. Finally, we selected miR-
21 as an oncogenic stromal signal which is abundant in 
exosomes, and demonstrated its importance in CRC 
progression using an orthotopic CRC model. Taken 
together, these results add weight to the evidence 
implicating exosomal miRNAs (exomiRs) in cancer 
progression, and particularly point a spotlight on the 
actions of miR-21.  
 




All patients were prospectively recruited as part of an 
ongoing UK National Institute of Health Research 
Clinical Research Network study (UKCRN ID 6067; 
NCT03309722), investigating the molecular pathology 
of CRC and designed to identify novel biomarkers. 
Other results and further details from this ongoing study 
have been previously reported [10, 37, 65, 66]. Study 
oversight activities and monitoring were performed at 
an independent clinical research organization. All 
patients provided written informed consent and the 
study was approved by the regional research ethics 
committee. Pathological verification of diagnosis and 
staging was in accordance with the Association of 
Coloproctology of Great Britain and Ireland guidelines 
[67]. Information relating to patient demographics, pre-
operative risk, imaging, surgery, pathological features, 
post-operative management and oncological outcomes 
were extracted. Exclusion criteria included evidence of 
a hereditary tumor, presence of multiple tumors, tumors 
with histologically identified extensive necrosis and 
tumors with synchronous metastases at presentation. 
Samples from patients with biopsy proven CRC were 
obtained fresh at the time of surgery. Patient charac-
teristics are summarized in Table 1. Three consecutive 
patients, none of whom had received neoadjuvant 
chemotherapy or radiotherapy, were prospectively in-
cluded. Immediately following excision  of  the  surgical 





















specimen, 1-2 cm diameter biopsies were taken from 
the tumor site and from normal colonic epithelium 
remote to the tumor, complying with the traditional 
view of resection margins in colorectal cancer surgery 
[68-70]. 
 
Extraction of primary fibroblasts 
 
We previously described a method for extracting 
primary fibroblasts from colorectal tissue specimens 
[71]. Briefly, fresh tissue was collected in 10 ml 
phosphate buffered saline (PBS) supplemented with 2% 
(double-strength) penicillin–streptomycin (Penicillin 
(200 U/mL)–streptomycin (200 μg/mL; Sigma-Aldrich, 
Saint Louis, USA) and 0.1% (0.25 μg/mL) amphotericin 
B (Fungizone; Thermo Fisher Scientific, Waltham, 
USA) and washed 3 times with PBS. Tumor and normal 
biopsies were divided into 2-3 mm fragments in sterile 
conditions. Each fragment was attached to one well in a 
12-well tissue culture plate containing Dulbecco’s 
Modified Eagle’s Medium (DMEM; Sigma-Aldrich, 
Saint Louis, USA) supplemented with 20% fetal calf 
serum (FCS), 2% penicillin–streptomycin and 0.1% 
amphotericin B, and incubated at 37°C/ 5% CO2. 
Growth medium was changed every 72 h. Outgrowth of 
fibroblasts was typically seen at 4 weeks, when cells 
were expanded in the standard manner. 
 
Isolation of exosomes 
 
Exosomes were isolated by differential ultra-
centrifugation as previously described [71]. Briefly, 
fibroblasts were grown to 70% confluency in 12 175 
cm2 flasks (3-4x107 cells), at which point the growth 
medium was replaced with equivalent medium contain-





















was harvested and centrifuged at 400 g for 5 min at 4oC 
to pellet cellular contaminant, followed by 2000 g for 
10 min at 4oC to pellet debris. The supernatant was then 
passed through a 0.22 μm filter and ultracentrifuged at 
100 000 g for 75 min at 4oC using the TFT 50.38 rotor 
(Sorvall, Cambridge, UK). The resulting exosome 
pellets were pooled, washed with PBS and ultra-
centrifuged again at 100 000 g. The final exosome pellet 
was solubilized in 200 μl PBS and stored at -80oC. We 
submitted all relevant data pertaining to exosome 
isolation and characterization to the EV-TRACK 
knowledgebase to assess the quality of our methodology 




Total cellular RNA was isolated using the miRNeasy 
mini kit (Qiagen, Hilden, Germany) and total exosomal 
RNA using the miRNeasy micro kit (Qiagen, Hilden, 
Germany), as per the manufacturer instructions. Briefly, 
700 μl QIAzol lysis reagent was added to the cells or 
exosomes and the sample disrupted and homogenized 
by passage through a 20G needle (cells) or vortexing for 
1 min (exosomes). The homogenate was then incubated 
at room temperature for 5 min. 140 μl chloroform was 
added to the homogenate, mixed thoroughly and 
incubated for a further 2 min at room temperature. The 
mixture was centrifuged at 12 000 g for 15 min at 4oC, 
after which the aqueous phase was collected. One and a 
half volumes of 100% ethanol were added to the 
aqueous phase and centrifuged in 700 μl aliquots 
through an RNeasy Mini (cells) or RNeasy MinElute 
(exosomes) spin column at 10 000 g for 15 s at room 
temperature. The spin column was then washed twice 
with RPE buffer (cells), or with RWT followed by RPE 
followed by 80% ethanol (exosomes). RNA was eluted 
Table 1. Demographic and clinical characteristics of study patients.  
 
Patient ID CRA-460-14 (1) CRA-463-14 (2) CRA-602-15 (3) 
Age (years) 79 68 79 
Sex F M M 
Ethnicity Caucasian Caucasian Caucasian 
Tumor Site Rectum Sigmoid Sigmoid 
pTNM T3N0M0 T4aN0M0 T4aN2M0 
AJCC Stage II II III 
Dukes’ Stage B B C1 
Differentiation Moderate Moderate Well-moderate 
EMVI Status Negative Negative Negative 
MSI Status Negative Negative Negative 
Neoadjuvant 
Treatment No No No 
pTNM, pathological TNM  stage  (5th edition); AJCC, American  Joint Committee on 
Cancer; EMVI, extramural vascular invasion; MSI, microsatellite instability 
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with 30 μl (cells) or 14 μl (exosomes) nuclease free 
water. RNA concentration and quality were measured 
by spectrophotometer (Nanodrop, Thermo Fisher, 
Waltham, USA) and Bioanalyzer (Agilent, Santa Clara, 
USA; Supplementary Fig. 1). 
 
NanoString miRNA profiling  
 
The multiplexed NanoString nCounter miRNA expres-
sion assay (NanoString Technologies, Seattle, USA) 
was used to profile 801 human miRNAs. The assay was 
performed according to the manufacturer’s protocol. 
Briefly, 100 ng of total RNA (33 ng/μl) was used as 
input material. A specific DNA tag was ligated to the 3′ 
end of each mature miRNA, providing exclusive 
identification for each miRNA species in the sample. 
The tagging was performed in a multiplexed ligation 
reaction utilizing reverse complementary bridge 
oligonucleotides to achieve ligation of each miRNA to 
its designated tag. All hybridization reactions were 
incubated at 64°C for 18 h. Excess tags were then 
removed and the resulting material was hybridized with 
a panel of fluorescently labeled, bar-coded, reporter 
probes specific to the miRNA of interest. Abundances 
of miRNAs were quantified on the nCounter Prep 
Station by counting individual fluorescent barcodes and 
quantifying target miRNA molecules present in each 
sample.   
 
NanoString data analysis  
 
Raw NanoString miRNA data were quantile-normalized 
using the voom function as implemented in the limma R 
package (version 3.30.9). MiRNAs were tested for 
differential abundance using an empirical Bayes 
moderated t-test in limma, and p-values were corrected 
for multiple testing by the positive false discovery rate. 
Results were then graphically displayed in a heat map 
showing the 20 largest changes in miRNA expression.  
 
Several other miRNAs (miR-21, miR-17-92 cluster, 
miR-95, miR-135a/b, miR-155 and miR-499) were 
selected based on their experimentally proven 
relevance in colorectal cancer and their roles as onco-
mirs [35]. Raw NanoString counts were normalized to 
miR-451, miR-16, miR-30a-5p and miR-30e-5p (a 
combination of best predicted and experimentally 
utilized stable endogenous exosomal miRNA controls 
[48, 49, 72]).  
 
To identify miRNAs that were enriched in exosomes, a 
global mean normalization method was used because 
there is no validated panel of miRNAs, which are stably 
expressed in both exosomal and cellular compartments 
[73]. For each miRNA of interest, exosomal levels were 
expressed relative to cellular miRNA levels.  
MiRNAs of interest were validated in a distinct 
biological replicate of the corresponding NanoString 
sample by RT-qPCR to ensure reproducibility. Relevant 
data were deposited in the ExoCarta database [74].  
 
TaqMan qPCR quantitation 
 
TaqMan Advanced (Thermo Fisher, Waltham, USA) 
miRNA assay reactions were performed to quantitate 
miRNA expression in cellular and exosomal RNA 
samples according to manufacturer instructions. The 
assay reference numbers were as follows: miR-16-5p 
(477860_mir), miR-21-5p (477975_mir), miR-29b-3p 
(478369_mir), miR-181a-3p (479405_mir), miR-199b-
5p (478486_mir), miR-215-5p (478516_mir), miR-329-
3p (478029_mir), miR-382-5p (478078_mir), miR-423-
5p (478090_mir). Briefly, for each sample, 4 ng of total 
RNA (2 ng/μl) was converted into cDNA following 
poly(A) tailing, adaptor ligation and reverse trans-
cription reactions. A further miR-amp reaction was then 
carried out on the reverse transcription product. PCR 
reactions were set up in triplicate using 20X miRNA 
assays and 2X Fast Advanced Master Mix (Thermo 
Fisher, Waltham, USA), and performed using the ABI 
7500 qPCR (Thermo Fisher, Waltham, USA) 
instrument with the following cycling parameters: 95°C 
for 20 s and 40 cycles of 95°C for 3 s/ 60oC for 30 s. 
Expression levels were normalized to miR-423-5p 
(endogenous reference gene) calculated from the 
triplicate of CT values using the ΔΔCT method, and 
expressed relative to one of the samples that was 
assigned the value 1. Mean relative levels were calcu-
lated for each sample. 
 
MiRNA pathway analysis 
 
Statistical relevance of potential biological pathways 
that could be affected by the changes observed in 
miRNA expression was calculated by the miRPath web-
based platform [64]. Putative miRNA target genes were 
determined using the homology search algorithm 
microT-CDS with the use of TarBase (database of >600 
000 experimentally validated interactions between 
miRNA and genes) [63]. For microT-CDS, a recom-
mended microT prediction threshold of greater than 0.8 
was set. The pathway enrichment analysis of multiple 
miRNA target genes was performed by comparing the 
input list to miRNA targets contained in all KEGG 
pathways. All significantly altered miRNAs were used 
simultaneously for the pathway enrichment analysis. 
The significance levels between miRNAs and every 
pathway were calculated by the Fisher-exact meta-
analysis method, with the use of unbiased empirical 
distribution [75]. The resulting p-values signify whether 
a pathway is targeted by at least one miRNA out of the 
selected group. P-values were adjusted using false 
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discovery rate (FDR) and significance level set to 0.05 
[76]. Relationships between miRNAs and small 
molecules were recovered using miRNet [60], which 
aggregates interaction data from multiple databases 
including TarBase, miR2Disease, HMDD, PhenomiR, 
SM2miR and PharmacomiR.  
 
Additionally, miRNAs of interest were submitted to 
the Ingenuity Pathway Analysis microRNA Target 
Filter (QIAGEN, https://www.qiagenbioinformatics.com/ 
products/features/microrna-target-filter). In this analy-
sis, mRNA targets and corresponding canonical path-
ways were predicted from a combination of TargetScan, 
TarBase, miRecords and the Ingenuity Knowledge Base.  
 
Cell lines and transfection 
 
DLD1, SW480, SW620 and HCT116 colorectal adeno-
carcinoma and MRC5 fetal lung fibroblast cells were 
procured from ATCC (Manassas, USA), where they had 
been characterized by STR profiling. Cells were grown 
in DMEM supplemented with 10% FCS and 2 mM L-
Glutamine, maintained at 37 °C in a humidified atmo-
sphere of 5% CO2, and passaged for fewer than 6 
months after receipt. 
 
MiR-21 and scrambled control (miR-SCC) miRNA 
were stably expressed in MRC5 fibroblasts by transfect-
ing precursor miRNA expression plasmids containing 
IRES-driven GFP reporters and subsequently selecting 
with puromycin (Genecopoeia, Rockville, USA). Trans-
fections were performed using the Xfect transfection 
reagent (Clontech Laboratories, Mountain View, USA). 
 
Stable mCherry expression in DLD1 cells was achieved 
by transfecting mCherry (N2) plasmid and selecting 
single cell clones with neomycin (Sigma-Aldrich, Saint 
Louis, USA). Positive clones were identified using 
fluorescence microscopy. Transfection was performed 
using the Lipofectamine 3000 transfection reagent 
(Thermo Fisher, Waltham, USA). 
 
Fluorescent labeling and transfer of exosomes 
 
Exosomes were isolated using the above method, up to 
and including the first 100 000 g ultracentrifugation. 
Pooled exosomes were then labeled with the lipophilic 
dye DiO (absorbance 484 nm, emission 501 nm) or DiD 
(absorbance 644 nm, emission 665 nm; Thermo Fisher, 
Waltham, USA) at a working concentration of 1:2500 
and incubated at 37oC for 20 min. Labeled exosomes 
were washed with PBS and centrifuged again at 100 000 
g for 75 min at 4oC.  
 
DiO-labeled exosomes were co-cultured with DLD1-
mCherry cells for 24 h at a concentration of 15 μg/ml, 
in a 6-well format. Cells were washed with PBS to 
remove ‘free’ exosomes and viewed at 10x using the 
Olympus CKX41 microscope (Olympus, Waltham, 
USA) in green and red channels. Acquired images were 
split into respective color channels and merged using 
ImageJ software (NIH; http://rsb.info.nih.gov/ij/). 
 
For flow cytometry, DiD-labeled exosomes were co-
cultured with DLD1 cells for 24 h at a concentration of 
15 μg/ml, in a 6-well format. Cells were washed with 
PBS, trypsinized, pelleted and re-suspended in 400 μl of 
DMEM.  The presence of exosomes in DLD cells was 
assessed by capturing DiD signal in the far red (FL4) 
channel using a flow cytometer (FACS Calibur, BD 
Biosciences, San Jose, USA). 
 
To investigate exosome-mediated miRNA changes in 
recipient cells, exosomes were co-cultured with DLD1 
and SW480 CRC cells at a concentration of 15 μg/ml 
for 24 h in a 6-well format. Control cells were treated 
with an equivalent volume of exosome-depleted con-
ditioned medium (supernatant remaining after exosome 
isolation). Twenty-four hours later, cells were washed 
with PBS to remove ‘free’ exosomes, pelleted and RNA 
extracted. Cellular levels of miR-16-5p, miR-21-5p, 
miR-29b-3p and miR-199b-5p were determined by RT-




DiO-labeled exosomes were co-cultured with DLD1-
mCherry cells for 24 h at 15 μg/ml on 22x22 mm glass 
microscope slides (VWR International, Fontenay-sous-
Bois, France). Cells were washed with PBS and fixed 
with ice-cold 50/50 acetone-methanol for 5 min after 
which the fixative was replaced with PBS. Cells were 
imaged using the Leica TCS SP5 confocal microscope 
at 60x (Leica Microsystems, Wetzlar, Germany). 
 
Immunostaining of actin filaments in primary 
fibroblasts 
 
Primary NOF and CAF cells (pair #2) were seeded on 
22x22 mm glass microscope slides (VWR International, 
Fontenay-sous-Bois, France) and grown to 70% 
confluency. Cells were washed with PBS, then fixed 
with ice-cold 50/50 acetone-methanol for 5 min. Cells 
were then incubated for 30 min with 50 μg/mL 
phalloidin-FITC (Sigma Aldrich, Saint Louis, USA), 
followed by 5 min with 1 μg/mL DAPI (Sigma Aldrich, 
Saint Louis, USA), then washed with PBS. Cells were 
viewed at 40x using the Olympus CKX41 microscope 
(Olympus, Waltham, USA). Staining intensity and 
surface area were measured for nine distinct cells in 
each field of view using ImageJ software (NIH; 
http://rsb.info.nih.gov/ij/). 
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Western blotting 
 
Cells or exosomes were lysed in 2X Laemmli buffer 
(4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.02% bromophenol blue and 120mM Tris HCl). 
Proteins were separated under reducing conditions in 8, 
10, 12 or 15% SDS-PAGE gels, transferred onto 
nitrocellulose membranes, detected with AKT (pan; 
C67E7; 1:1000), phospho-AKT (Ser473; D9E; 1:1000), 
Bad (D24A9; 1:1000),  phospho-Bad (Ser136/99; 
D25H8; 1:1000), cytochrome C (4272; 1:1000; Cell 
Signaling Technology, Danvers, USA), Alix (3A9; 
1:500), TSG101 (4A10; 1:500; Abcam, Cambridge, 
UK), CD63 (Ts63; 1:500), CD81 (1.3.3.22; 1:500; 
Thermo Fisher, Waltham, USA), GM130 (35/GM130; 
1:500; BD Biosciences, Oxford, UK), α-SMA, (1A4; 
1:2000; Sigma-Aldrich, Saint Louis, USA), FN1-EDA 
(MAB1940; 1:2000; Merck Millipore, Burlington, 
USA), palladin (1E6; 1:1000; Novus Biologicals, 
Littleton, USA), Vimentin (Vim 3B4; 1:1000; Dako, 
Glostrup, Denmark) primary antibodies and horseradish 
peroxidase-conjugated secondary antibodies (1:4000; 
Dako, Glostrup, Denmark). Specific signal was 
visualized using the SuperSignal West Dura Chemi-
luminescent detection kit (Thermo Scientific, Waltham, 
USA). Membranes were probed for β-actin (C4; 1:5000; 
BD Biosciences, San Jose, USA), HSP90 (1:1000; Cell 
Signaling Technology, Danvers, USA) or HSC-70, (B-





There were four experimental conditions: (i) DLD1 
cells, (ii) DLD1 cells treated with oxaliplatin, (iii) 
DLD1 cells co-cultured with MRC5 exosomes and (iv) 
DLD1 cells co-cultured with MRC5 exosomes and 
treated with oxaliplatin. Where applicable, DLD1 cells 
were co-cultured for 24 h with MRC5 exosomes at a 
concentration of 15 μg/mL, after which they were 
washed with PBS to remove ‘free’ exosomes. Where 
exosomes were not used, exosome-depleted conditioned 
medium of equivalent volume was used as a control. 
Oxaliplatin (Sigma-Aldrich, Saint Louis, USA) was 
used at a working concentration of 200 μM for 24 h, 
and where applicable, was added to the growth media 
after the 24 h exosome co-culture.  
 
For subG1 DNA analysis the protocol described by 
Sayan et al. was used [77]. Briefly, cells were detached, 
pelleted, fixed with 70% ice-cold ethanol and stored at -
20oC overnight. Next morning, cells were centrifuged at 
500 g for 5 min and fixation solution discarded. Cells 
were then re-suspended in 100 μl PBS by gentle 
vortexing. To stain for DNA, cells were incubated with 
0.260 U RNase (in PBS) for 30 min followed by 50 μM 
propidium iodide (in PBS) for 30 min. SubG1 DNA 
content was analyzed using a flow cytometer (FACS 





DLD1 cells were seeded in quadruplicate at a density of 
1000 /well in a 96 well plate. The following day (day 
0), MRC5 exosomes were added to achieve a 
concentration of 15 μg/ml. An equivalent volume of 
exosome-depleted conditioned medium was added to 
control cells. Cells were fixed sequentially on days 0, 2, 
3, 4 and 5 with ice-cold 50/50 acetone-methanol. On 
day 5, all cells were stained with 1 μg/mL DAPI, 
washed with PBS, and the center of each well viewed at 
4x using a fluorescence microscope with UV filter 
(CKX41, Olympus, Waltham, USA). Cell nuclei were 
counted using ImageJ software (NIH; 
http://rsb.info.nih.gov/ij/) as previously described [78]. 
 
Transmission electron microscopy 
 
Following exosome isolation, the washed pellet was 
resuspended in 100 μl ultrapure water and stored at 4oC 
for up to 7 days prior to processing. Briefly, 10 μl 
exosome sample was dropped on to Parafilm (Bemis 
NA, Neenah, USA). A carbon coated formvar copper 
grid (EM Resolutions, Saffron Walden, UK) was placed 
on the droplet to immerse its coated side, and incubated 
for 30 s at room temperature. Excess sample was blotted 
away using absorbent paper. Similarly, the grid was 
incubated with 10 μl negative stain (5% ammonium 
molybdate/ 1% trehalose) for 10 s. Excess negative 
stain was removed by blotting. The grid was visualized 
at increasing magnification up to 120 000x using the 
Tecnai 12 microscope (FEI, Lausanne, Switzerland). 
 
Nanoparticle tracking analysis 
 
The size distribution of exosomes was measured by 
nanoparticle tracking analysis (NS300; NanoSight, 
Amesbury, UK), equipped with an EMCCD camera and 
a 405 nm diode laser. Silica beads (100 nm diameter; 
Microspheres-Nanospheres, Cold Spring, NY) were 
used to calibrate the instrument. Exosome samples were 
diluted 1:5000 in double filtered PBS to optimize 
particle number in the field of view. For each sample, 
five videos, each of 90-seconds duration, were captured. 
Analysis was performed using the instrument software 
(NTA 2.3.0.15). 
 
In vivo studies 
 
All mice were housed in a specific pathogen-free 
facility at the University of Southampton and given a 
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commercial basal diet and water ad libitum. To 
demonstrate persistence of injected fibroblasts in vivo, 
three 6-8 week old female CD-1 nude mice (Charles 
River, Margate, UK) were co-injected with 5x105 
HCT116 CRC cells and 5x105 PKH26-labelled MRC5 
fibroblasts into dorsal subcutaneous tissue bilaterally. 
MRC5 cells were labelled with PKH26 (excitation 551 
nm, emission 567 nm; Sigma-Aldrich, Saint Louis, 
USA) as per manufacturer instructions. At five weeks, 
animals were humanely euthanized and tumors excised. 
Tumors were fixed in 2% paraformaldehyde for two 
hours at 4oC, cryoprotected in 30% sucrose overnight at 
4oC, embedded in OCT medium (Electron Microscopy 
Sciences, Hatfield, USA) and snap frozen before 
cryosectioning. Mounted sections were imaged at 60x 
using the Leica TCS SP5 confocal microscope (Leica 
Microsystems, Wetzlar, Germany). 
 
An orthotopic colorectal cancer model was used as 
previously described [37]. Briefly, six 6-8 week old 
female CD-1 nude mice (Charles River, Margate, UK) 
were anaesthetized under isoflurane anesthesia followed 
by laparotomy and exteriorization of the caecum. For 
each animal, 1x106 SW620 human CRC cells and 5x106 
human MRC5 fibroblasts (stably expressing miR-21 or 
scrambled sequence control miRNA; n=3 in each 
group) were combined with Matrigel (Corning, New 
York, USA) to a total volume of 200 μl. The cell/ matrix 
combination was orthotopically co-injected into the 
submucosal layer of the cecum under magnified vision. 
The cecum was then returned to the peritoneal cavity 
and the abdominal wall closed in layers with absorbable 
suture material. Tumors were allowed to grow for 8-10 
weeks until the first mice showed signs of weight loss, 
at which time all mice were humanely euthanized. 
Colon, liver and spleen were harvested. Excised tissue 
was paraffin embedded, stained with hematoxylin and 
eosin and mounted on to slides, before assessment by a 
specialist histopathologist who was blinded to the 
outcome of the experiment. Percentage liver replace-
ment (surface area of tumor relative to total surface 
area) for multiple sections of each control and “miR-21” 
liver was measured using ImageJ software (NIH; 
http://rsb.info.nih.gov/ij/). Values from each section 




Where individual images (microscopy, western blotting, 
NTA and flow cytometry) are displayed, these are 
representative of at least 2 separate experiments. 
Graphics represent the mean ± SEM, unless otherwise 
stated. The threshold level of significance was set at 
0.05 for all statistical tests. RT-qPCR was performed in 
triplicate and differences in mean relative values were 
tested by 2-tailed, paired or unpaired (Student’s) t-test, 
as appropriate. Cell counting was performed in 
quadruplicate and differences in mean relative counts 
were compared by paired t-test. Events acquired by 
flow cytometry were analyzed in a 2x2 contingency 
table by a 2-tailed Fisher’s exact test using the “sum of 
small p-values” method. Percentage liver replacement 
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KEGG Pathway p-value Genes miRNAs 
MicroRNAs in cancer 9.24E-30 54 4 
ECM-receptor interaction 4.32E-21 19 4 
Prion diseases 1.20E-16 7 2 
Proteoglycans in cancer 2.58E-09 52 4 
Glioma 4.67E-08 24 4 
Colorectal cancer 3.86E-06 23 4 
Hepatitis B 9.78E-06 39 4 
Non-small cell lung 
cancer 1.91E-04 20 4 
Pathways in cancer 1.91E-04 79 4 
Bladder cancer 3.54E-04 18 4 
Endometrial cancer 3.54E-04 19 4 
Pancreatic cancer 4.51E-04 24 4 
Lysine degradation 5.24E-04 14 2 
FoxO signaling pathway 1.01E-03 38 4 
Fatty acid elongation 1.04E-04 7 2 
PI3K-Akt signaling 
pathway 1.22E-03 71 4 
Focal adhesion 1.31E-03 52 4 
Central carbon 
metabolism in cancer 1.39E-03 20 4 
Chronic myeloid 
leukemia 1.50E-03 24 4 
Melanoma 1.63E-03 22 4 
Thyroid hormone 
signaling pathway 3.61E-03 29 4 
 















































































ErbB signaling pathway 3.97E-03 23 4 
Prostate cancer 4.21E-03 27 4 
Small cell lung cancer 4.21E-03 25 4 
Thyroid cancer 6.83E-03 10 4 
HIF-1 signaling pathway 7.72E-03 29 3 
Amoebiasis 1.23E-02 26 4 
mTOR signaling pathway 1.65E-02 19 4 
Renal cell carcinoma 1.95E-02 19 4 
Hippo signaling pathway 3.11E-02 29 4 
Prolactin signaling 
pathway 3.17E-02 18 4 
Choline metabolism in 
cancer 4.39E-02 25 4 
Adherens junction 4.46E-02 18 3 
MAPK signaling pathway 4.46E-02 51 4 




Name p-value Molecules 
Cancer 4.87E-02 - 3.31E-09 6 
Organismal Injury and Abnormalities 4.87E-02 - 3.31E-09 6 
Reproductive System Disease 4.82E-02 - 3.31E-09 5 
Connective Tissue Disorders 4.06E-02 - 1.23E-04 2 




Name p-value Molecules 
Cellular Development 2.03E-02 - 3.67E-05 4 
Cellular Growth and Proliferation 2.03E-02 - 3.67E-05 4 
Cell Morphology 4.17E-02 - 5.62E-04 2 
Cell-To-Cell Signaling and Interaction 7.84E-03 - 5.62E-04 2 
Cellular Movement 3.62E-02 - 8.42E-04 2 

















































































miRNA Molecule Pubchem ID Experiment Pubmed ID 
hsa-mir-21-5p 5-fluorouracil 3385 Microarray 21506117 
hsa-mir-21-5p 5-aza-2'-deoxycytidine (5-Aza-CdR) 451668 Microarray 22076154 
hsa-mir-21-5p 17beta-estradiol (E2) 5757 Microarray 22403704 
hsa-mir-21-5p 5-fluorouracil 3385 qRT-PCR 17702597 
  5757 Microarray 19528081 
hsa-mir-21-5p 3,3'-diindolylmethane (BR-DIM) 3071 qRT-PCR 20724916 
hsa-mir-21-5p 5-aza-2'-deoxycytidine (5-Aza-CdR) 451668 Microarray 22076154 
hsa-mir-21-5p 17beta-estradiol (E2) 5757 qRT-PCR 22403704 
hsa-mir-21-5p  CDF (analogues of curcumin) + gemcitabine N/A qRT-PCR 20388782 
hsa-mir-21-5p  Cisplatin 84093 qRT-PCR 22475935 
hsa-mir-21-5p  Curcumin 969516 Microarray 18347134 
hsa-mir-21-5p  Curcumin 969516 qRT-PCR 22363450 
hsa-mir-21-5p  Diazobenzene and its derivatives N/A 
Luciferase reporter 
assay 18712719 
hsa-mir-21-5p  17beta-estradiol (E2) 5757 qRT-PCR 19264808 
hsa-mir-21-5p  Curcumin 969516 qRT-PCR 20815812 
hsa-mir-21-5p  Bisphenol A 6623 Microarray 20417706 
hsa-mir-21-5p  Bisphenol A 6623 Microarray 20417706 
hsa-mir-21-5p  Bisphenol A 6623 Microarray 22403704 
hsa-mir-21-5p  Caudatin 21633059 qRT-PCR 23708208 
hsa-mir-21-5p  CDF (analogues of curcumin) N/A qRT-PCR 20388782 
hsa-mir-21-5p  Gemcitabine 60750 qRT-PCR 24460329 
hsa-mir-21-5p  Gemcitabine 60750 qRT-PCR 21738581 
hsa-mir-21-5p  Ginsenoside Rh2 119307 Microarray 21372826 
hsa-mir-21-5p  Ginsenoside Rh2 119307 qRT-PCR 21372826 
hsa-mir-21-5p  Ginsenoside Rh2 119307 Microarray 23152132 
hsa-mir-21-5p  Glossy ganoderma spore oil N/A qRT-PCR 21842656 
hsa-mir-21-5p  Dihydrotestosterone (DHT) 10635 Microarray 20945501 
hsa-mir-21-5p  17beta-estradiol (E2) 5757 qRT-PCR 19528081 
hsa-mir-21-5p  Hydroxamic acid HDACi LAQ824 N/A Microarray 16452179 
hsa-mir-21-5p  Hydroxychloroquine 3652 Microarray 24121037 
hsa-mir-21-5p  Hydroxychloroquine 3652 qRT-PCR 24121037 
hsa-mir-21-5p  Marine fungal metabolite 1386A N/A Microarray 22159329 
hsa-mir-21-5p  Gemcitabine 60750 Northern blot 16762633 
hsa-mir-21-5p  Microcystin-LR (MC-LR) 445434 qRT-PCR 22265967 
hsa-mir-21-5p  Nicotine 89594 qRT-PCR 24756761 
hsa-mir-21-5p  Nicotine 89594 qRT-PCR 21081469 
hsa-mir-21-5p  N-methyl-N-nitro-N'-nitrosogua nidine (MNNG) 9576410 qRT-PCR 24821435 
hsa-mir-21-5p  5-fluorouracil 3385 qRT-PCR 21506117 
hsa-mir-21-5p  All-trans-retinoic acid (ATRA) 444795 Microarray 21131358 
hsa-mir-21-5p  Glucocorticoid N/A qRT-PCR 22815788 
hsa-mir-21-5p  Glucocorticoid N/A TaqMan low-density array 22815788 















































































hsa-mir-21-5p  Arsenite 544 qRT-PCR 24004609 
hsa-mir-21-5p  Sulindac sulfide 5352624 qRT-PCR 22286762 
hsa-mir-21-5p  Sunitinib 5329102 qRT-PCR 25061297 
hsa-mir-21-5p  Temozolomide 5394 qRT-PCR 22753745 
hsa-mir-21-5p  Matrine 91466 qRT-PCR 22832383 
hsa-mir-21-5p  Trastuzumab N/A qRT-PCR 22384020 
hsa-mir-21-5p  Trastuzumab N/A Microarray 22384020 
hsa-mir-21-5p  Trichostatin A (TSA) 444732 Microarray 19112422 
hsa-mir-21-5p  Trichostatin A (TSA) 444732 Northern blot 19112422 
hsa-mir-21-5p  Trimetazidine (TMZ) 21109 qRT-PCR 22842854 
hsa-mir-21-5p  Triptolide 107985 qRT-PCR 22957792 
hsa-mir-21-5p  Trypaflavine N/A qRT-PCR 20529860 
hsa-mir-21-5p  Valproate 3121 qRT-PCR 20427269 
hsa-mir-21-5p  Dihydrotestosterone (DHT) 10635 qRT-PCR 20945501 
hsa-mir-21-5p  Doxorubicin 31703 Microarray 19237188 
hsa-mir-21-5p  Enoxacin 3229 qRT-PCR 21368194 
hsa-mir-21-5p  Etoposide 36462 Microarray 19633716 
hsa-mir-21-5p  Trastuzumab N/A Microarray 22384020 
hsa-mir-21-5p  Formaldehyde 712 Microarray 21147603 
hsa-mir-21-5p  Progesterone 5994 Microarray 22543862 
hsa-mir-21-5p  CDF (analogues of curcumin) 
+ gemcitabine N/A qRT-PCR 21408027 
hsa-mir-21-5p  All-trans-retinoic acid 
(ATRA) 444795 qRT-PCR 21131358 
hsa-mir-21-5p  Arsenic trioxide 14888 qRT-PCR 22072212 
hsa-mir-21-5p  O,p'-dichlorodiphenyltrichlo-
roethane (DDT) 13089 Microarray 22403704 
hsa-mir-21-5p  Prednisone 5865 qRT-PCR 24121037 
hsa-mir-21-5p  Morphine 5288826 Microarray 20564181 















































































hsa-mir-21-5p  CDF (analogues of curcumin) N/A qRT-PCR 21408027 
hsa-mir-21-5p  Prednisone 5865 Microarray 24121037 
hsa-mir-21-5p  Polylysine 162282 qRT-PCR 20529860 
hsa-mir-199b-5p  Imatinib mesylate 123596 qRT-PCR 20460641 
hsa-mir-199b-5p  Imatinib mesylate 123596 TaqMan low-density array 20460641 
hsa-mir-199b-5p  Glucose 5793 qRT-PCR 24394957 
hsa-mir-199b-5p  4-hydroxynonenal 5283344 Microarray 19022373 
hsa-mir-199b-5p  Enoxacin 3229 qRT-PCR 18641635 
hsa-mir-181a-3p  Gemcitabine 60750 Microarray 19237188 
hsa-mir-181a-3p  Curcumin 969516 qRT-PCR 22510010 
hsa-mir-181a-3p  Doxorubicin 31703 Microarray 19237188 
hsa-mir-181a-3p  Gemcitabine 60750 Northern blot 16762633 
hsa-mir-181a-3p  4-hydroxynonenal 5283344 Microarray 19022373 
hsa-mir-181a-3p  Diethylstilbestrol 448537 Microarray 19549897 
hsa-mir-215-5p  Trichostatin A (TSA) 444732 Microarray 21971930 
hsa-mir-215-5p  Formaldehyde 712 Microarray 21147603 
hsa-mir-215-5p Arsenic trioxide 14888 qRT-PCR 22072212 
hsa-mir-382-5p Morphine 5288826 qRT-PCR 21224041 
hsa-mir-382-5p Vorinostat (SAHA) 5311 Microarray 19513533 
hsa-mir-329-3p Glucose 5793 Microarray 24394957 
hsa-mir-329-3p Gemcitabine 60750 Northern blot 16762633 
 















































































Supplementary  Figure  1.  Assessment  of  RNA  by  Bioanalyzer  reveals  distinct  cellular  and  exosomal  profile.
















































































Supplementary  Figure 2.  SubG1  analysis by  flow  cytometry demonstrates protective  effect of















































































(y‐axis).  This  is  an  alternative  representation  of  data  displayed  in  the  previous  heat map  (Fig.  5).  Threshold  of
statistical significance set at 0.05.  

































































































Supplementary  Figure  6.  CAF‐derived  exosomal  miRNAs  converge  on  multiple
cancer‐relevant pathways. Statistical significance of 36 KEGG pathways co‐regulated by miR‐
329‐3p, miR‐181a‐3p, miR‐199b‐5p, miR‐382‐5p, miR‐215‐5p and miR‐21‐5p. Data represented
as –log 10 (p value). Fisher‐exact meta‐analysis method with FDR‐adjusted p‐values. 
 
